Financial Report: Catalent

Catalent
 
1Q Revenues: $442.2 million (+5%)

1Q Earnings: $4.6 million (earnings were $11.7 million 1Q16)

Comments: Revenue from the Softgel Technologies segment was $186.4 million, an increase of 1%. Revenue from the Drug Delivery Solutions segment was $191.3 million, up 10% primarily driven by volumes related to fee-for-service development and analytical testing in the U.S., the company’s biologics offering and European pre-filled syringe operations. This growth was partially offset by decreased volume in integrated oral solids development and manufacturing capabilities. Revenue from the Clinical Supply Services segment was $75.0 million, down 3%.